Severity of Diabetes in MELAS and MERRF May Rather Reflect Genotype and Comorbidities than Histology of Islet Cells
Himalayan Journal of Community Medicine and Public Health · 2020
DOI: 10.47310/hjcmph.2020.v01i01.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Himalayan Journal of Community Medicine and Public Health, 2020. Verfasst von Josef Finsterer und 1 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
With interest we read the article by Norose et al. about the histological and immune-histological findings of islet cells in two patients with mitochondrial diabetes [1]. One patient was diagnosed with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome due to the variant m.3243A>G (patient-1) and the second patient was diagnosed with myoclonic epilepsy with ragged-red fibers (MERRF) syndrome due to the variant m.8344A>G [1]. Patient-1 required insulin, whereas patient-2 did not require any anti-diabetic treatment [1]. It was concluded that the severity of diabetes correlates with the severity of the histological and immune-histological findings on autopsy [1]. We have the following comments and concerns.
Zitieren
APA
Finsterer, J., & Frank, M. (2020). Severity of Diabetes in MELAS and MERRF May Rather Reflect Genotype and Comorbidities than Histology of Islet Cells. Himalayan Journal of Community Medicine and Public Health. https://doi.org/10.47310/hjcmph.2020.v01i01.004
Vancouver
Finsterer J, Frank M. Severity of Diabetes in MELAS and MERRF May Rather Reflect Genotype and Comorbidities than Histology of Islet Cells. Himalayan Journal of Community Medicine and Public Health. 2020. doi:10.47310/hjcmph.2020.v01i01.004
BibTeX
@article{Finsterer2020,
author = {Finsterer, Josef and Frank, Marlies},
title = {Severity of Diabetes in MELAS and MERRF May Rather Reflect Genotype and Comorbidities than Histology of Islet Cells},
journal = {Himalayan Journal of Community Medicine and Public Health},
year = {2020},
doi = {10.47310/hjcmph.2020.v01i01.004}
}
EUVIMED